Bupivacaine
Bupivacaine
Bupivacaine
Thermo Scientific Chemicals

Bupivacaine

Bupivacaine, CAS # 38396-39-3, is a potent and long-acting in vivo local anesthetic agent. | CAS: 38396-39-3 | C18H28N2O | 288.44 g/mol
Have Questions?
Change viewbuttonViewtableView
Quantity:
1 g
5 g
25 g
This chemical may require us to obtain additional information for our regulatory and chemical compliance records. If required, we will contact you for this information once your order is placed.
Catalog number J62742.03
also known as J62742-03
Price (USD)
153.65
Special offer
Online exclusive
Ends: 26-Sep-2025
189.00
Save 35.35 (19%)
Each
Add to cart
Quantity:
1 g
Request bulk or custom format
Price (USD)
153.65
Special offer
Online exclusive
Ends: 26-Sep-2025
189.00
Save 35.35 (19%)
Each
Add to cart
Chemical Identifiers
CAS38396-39-3
SpecificationsSpecification SheetSpecification Sheet
FormPowder or crystals or crystalline powder
Identification (FTIR)Conforms
Appearance (Color)White to off-white
Assay from Supplier's CofA≥97.0%
Loss on Drying≤0.5%

Bupivacaine acts as a potent and long-acting local anesthetic agent in vivo. At 100 μM, it has been reported to inhibit the uptake of dopamine in striatal synaptosomes by 47%.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Application

  • Bupivacaine has been shown to activate the AMPKα/BDNF signaling pathway in spinal astrocytes
RUO – Research Use Only

General References:

  1. Chahar P & Cummings KC. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012, 5, (pt 12), 257-64.
  2. Covino BG Pharmacology of local anaesthetic agents. Br J Anaesth. 1986, 58, (7), 701-16.
  3. Paganelli MA, Popescu GK. Actions of bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci. 2015 Jan 14;35(2):831-42. doi: 10.1523/JNEUROSCI.3578-14.2015. PMID: 25589775; PMCID: PMC4293426.
  4. Lu K, Zhao L, Zhang Y, Yang F, Zhang H, Wang J, Li B, Ji G, Yu J, Ma H. Bupivacaine reduces GlyT1 expression by potentiating the p-AMPKα/BDNF signalling pathway in spinal astrocytes of rats. Sci Rep. 2022 Jan 26;12(1):1378. doi: 10.1038/s41598-022-05478-3. PMID: 35082359; PMCID: PMC8792009.

Share catalog number, name or link